ACTIV-2
ACTIV-2 (Adaptive Platform Treatment Trial for Outpatients with COVID-19 (Adapt Out COVID)) IRB#: 22976
The outpatient trial enrolled adults with COVID-19 who are symptomatic but do not require hospitalization. Study aims to evaluate safety and efficacy of monoclonal antibody treatment, which consist of SAB-185 blinded placebo-controlled trial infusion. Participants who have been enrolled will be given the option to receive standard of care COVID-19 therapies, if the participants desire it. Enrolled subjects will be followed for 72 weeks, with 3 in person visits in first month.